Journal List > Brain Neurorehabil > v.9(1) > 1054768

Min: Diagnosis and Treatment of Restless Legs Syndrome

Abstract

Restless legs syndrome (RLS) is a neurological disorder characterized by an irresistible urge to move one's body to stop uncomfortable or odd sensations. It most commonly affects the legs. Moving the affected body part, such as walking or stretching provide relief the urge to move the legs and any accompanying unpleasant sensation partially or totally. RLS is relatively common, affecting 5 to 15 % of the general population, with prevalence rates increasing alongside age. Restless legs syndrome can lead to sleep-onset or sleep-maintenance insomnia, and occasionally excessive daytime sleepiness, all leading to significant morbidity. Dopaminergic systems are known to be strongly related with RLS that are closely linked to CNS iron homeostasis. Besides defective dopaminergic system that is closely related with iron metabolism, genetic factors play a role in early-onset individual with a positive family history. The diagnosis can be made based on the symptom characteristics, differential diagnosis is important because many conditions could mimic RLS symptoms. Dopamine agonists (DAs) have been considered the first-line therapy, but with the growing appreciation of problems associated with long-term treatment, particularly augmentation and impulse control disorder, alpha-2-delta drugs, such as gabapentin, are now considered the first line of treatment in patients with troublesome RLS. In more severe cases, a combination therapy may be required.

Figures and Tables

Table 1

International Restless Legs Syndrome Study Group (IRLSSG) Consensus Diagnostic Criteria for Restless Legs Syndrome (RLS)

bn-9-25-i001
Essential diagnostic criteria (all must be met):
 1. An urge to move the legs usually but not always accompanied by, or felt to be caused by, uncomfortable and unpleasant sensations in the legs.
 2. The urge to move the legs and any accompanying unpleasant sensations begin or worsen during periods of rest or inactivity such as lying down or sitting.
 3. The urge to move the legs and any accompanying unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues.
 4. The urge to move the legs and any accompanying unpleasant sensations during rest or inactivity only occur or are worse in the evening or night than during the day.
 5. The occurrence of the above features is not solely accounted for as symptoms primary to another medical or a behavioral condition (e.g. myalgia, venous stasis, leg edema, arthritis, leg cramps, positional discomfort, habitual foot tapping).
Specifiers for clinical course of RLS:
 A. Chronic-persistent RLS: symptoms when not treated would occur on average at least twice weekly for the past year.
 B. Intermittent RLS: symptoms when not treated would occur on average
Specifier for clinical significance of RLS:
 The symptoms of RLS cause significant distress or impairment in social, occupational, educational or other important areas of functioning by their impact on sleep, energy/vitality, daily activities, behavior, cognition or mood.

References

1. Restless legs syndrome: detection and management in primary care. National Heart, Lung, and Blood Institute Working Group on Restless Legs Syndrome. Am Fam Physician. 2000; 62:108–114.
2. Cho YW, Shin WC, Yun CH, Hong SB, Kim JH, Allen RP, Earley CJ. Epidemiology of restless legs syndrome in Korean adults. Sleep. 2008; 31:219–223.
crossref
3. Berger K, Luedemann J, Trenkwalder C, John U, Kessler C. Sex and the risk of restless legs syndrome in the general population. Arch Intern Med. 2004; 164:196–202.
crossref
4. Hattan E, Chalk C, Postuma RB. Is there a higher risk of restless legs syndrome in peripheral neuropathy? Neurology. 2009; 72:955–960.
crossref
5. Evidente VG, Adler CH. How to help patients with restless legs syndrome. Discerning the indescribable and relaxing the restless. Postgrad Med. 1999; 105:59–61. 65–66. 73–74.
6. Cesnik E, Casetta I, Turri M, Govoni V, Granieri E, Strambi LF, Manconi M. Transient RLS during pregnancy is a risk factor for the chronic idiopathic form. Neurology. 2010; 75:2117–2120.
crossref
7. Takaki J, Nishi T, Nangaku M, Shimoyama H, Inada T, Matsuyama N, Kumano H, Kuboki T. Clinical and psychological aspects of restless legs syndrome in uremic patients on hemodialysis. Am J Kidney Dis. 2003; 41:833–839.
crossref
8. Lane RM. SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment. J Psychopharmacol. 1998; 12:192–214.
crossref
9. Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisi J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003; 4:101–119.
crossref
10. Abetz L, Allen R, Follet A, Washburn T, Earley C, Kirsch J, Knight H. Evaluating the quality of life of patients with restless legs syndrome. Clin Ther. 2004; 26:925–935.
crossref
11. Ekbom K, Ulfberg J. Restless legs syndrome. J Intern Med. 2009; 266:419–431.
crossref
12. Kim JB, Koo YS, Eun MY, Park KW, Jung KY. Psychosomatic symptom profiles in patients with restless legs syndrome. Sleep Breath. 2013; 17:1055–1061.
crossref
13. American Academy of Sleep Medicine. The International Classification of Sleep Disorders. 2nd ed. Westchester, Illinois: 2005.
14. Eun MY, Seok HY, Kim JB, Jung KY. Comparison of Sleep Quality and Polysomnographic Findings in Patients with RLS according to the Presence of Periodic Limb Movements during Sleep. J Korean Sleep Res Soc. 2012; 8:4–8.
crossref
15. Allen RP, Earley CJ. Restless legs syndrome: a review of clinical and pathophysiologic features. J Clin Neurophysiol. 2001; 18:128–147.
16. Winkelman JW. Considering the causes of RLS. Eur J Neurol. 2006; 13:Suppl 3. 8–14.
crossref
17. Connor JR, Ponnuru P, Wang XS, Patton SM, Allen RP, Earley CJ. Profile of altered brain iron acquisition in restless legs syndrome. Brain. 2011; 134:959–968.
crossref
18. Trenkwalder C, Hogl B, Winkelmann J. Recent advances in the diagnosis, genetics and treatment of restless legs syndrome. J Neurol. 2009; 256:539–553.
crossref
19. Hening WA, Allen RP, Washburn M, Lesage SR, Earley CJ. The four diagnostic criteria for Restless Legs Syndrome are unable to exclude confounding conditions ("mimics"). Sleep Med. 2009; 10:976–981.
crossref
20. Hening WA, Allen RP, Thanner S, Washburn T, Heckler D, Walters AS, Earley CJ. The Johns Hopkins telephone diagnostic interview for the restless legs syndrome: preliminary investigation for validation in a multi-center patient and control population. Sleep Med. 2003; 4:137–141.
crossref
21. Gamaldo CE, Earley CJ. Restless legs syndrome: a clinical update. Chest. 2006; 130:1596–1604.
22. Hening WA. Restless Legs Syndrome. Curr Treat Options Neurol. 1999; 1:309–319.
crossref
23. Ferreri F, Rossini PM. Neurophysiological investigations in restless legs syndrome and other disorders of movement during sleep. Sleep Med. 2004; 5:397–399.
crossref
24. Giannaki CD, Hadjigeorgiou GM, Karatzaferi C, Maridaki MD, Koutedakis Y, Founta P, Tsianas N, Stefanidis I, Sakkas GK. A single-blind randomized controlled trial to evaluate the effect of 6 months of progressive aerobic exercise training in patients with uraemic restless legs syndrome. Nephrol Dial Transplant. 2013; 28:2834–2840.
crossref
25. Mitchell UH. Medical devices for restless legs syndrome - clinical utility of the Relaxis pad. Ther Clin Risk Manag. 2015; 11:1789–1794.
26. Montplaisir J, Nicolas A, Denesle R, Gomez-Mancilla B. Restless legs syndrome improved by pramipexole - A double-blind randomized trial. Neurology. 1999; 52:938–943.
crossref
27. Ondo W. Ropinirole for restless legs syndrome. Mov Disord. 1999; 14:138–140.
crossref
28. Giorgi L, Asgharian A, Hunter B. Ropinirole in Patients With Restless Legs Syndrome and Baseline IRLS Total Scores >= 24: Efficacy and Tolerability in a 26-Week, Double-Blind, Parallel-Group, Placebo-Controlled Study Followed by a 40-Week Open-Label Extension. Clin Ther. 2013; 35:1321–1336.
crossref
29. Baldwin CM, Keating GM. Rotigotine transdermal patch - In restless legs syndrome. Cns Drugs. 2008; 22:797–806.
30. Garcia-Borreguero D, Allen RP, Kohnen R, Hogl B, Trenkwalder C, Oertel W, Hening WA, Paulus W, Rye D, Walters A, Winkelmann J, Earley CJ. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med. 2007; 8:520–530.
31. Manconi M, Ferri R, Zucconi M, Bassetti CL, Fulda S, Arico D, Ferini-Strambi L. Dissociation of periodic leg movements from arousals in restless legs syndrome. Ann Neurol. 2012; 71:834–844.
crossref
32. Bogan RK, Bornemann MAC, Kushida CA, Tran PV, Barrett RW, Grp XS. Long-term Maintenance Treatment of Restless Legs Syndrome With Gabapentin Enacarbil: A Randomized Controlled Study. Mayo Clin Proc. 2010; 85:512–521.
crossref
TOOLS
Similar articles